<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pneumonia caused by &lt;i&gt;Chlamydia pneumoniae&lt;/i&gt; in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pneumonia caused by <i>Chlamydia pneumoniae</i> in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pneumonia caused by <i>Chlamydia pneumoniae</i> in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Margaret R Hammerschlag, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas M File, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Chlamydia pneumoniae </em>is an obligate intracellular bacterium that causes respiratory tract infections including pharyngitis, bronchitis, and pneumonia. Pneumonia caused by <em>C. pneumoniae</em> is typically community acquired and mild.</p><p>Pneumonia caused by <em>C. pneumoniae</em> in adults will be discussed here. Pneumonia caused by <em>C. psittaci</em>, a zoonotic <em>Chlamydia</em> species that can also cause respiratory infections in humans, is discussed separately (see  <a class="medical medical_review" href="/d/html/7015.html" rel="external">"Psittacosis"</a> and  <a class="medical medical_review" href="/d/html/5957.html" rel="external">"Pneumonia caused by <i>Chlamydia pneumoniae</i> in children"</a>). Pneumonia due to <em>Chlamydia trachomatis</em>, which is limited to infants, is discussed separately. (See  <a class="medical medical_review" href="/d/html/4993.html" rel="external">"Chlamydia trachomatis infections in the newborn"</a>.)</p><p>The epidemiology, clinical features, diagnosis, and management of community-acquired pneumonia are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6990.html" rel="external">"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7016.html" rel="external">"Morbidity and mortality associated with community-acquired pneumonia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5987.html" rel="external">"Community-acquired pneumonia in children: Outpatient treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2675378800"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>The term "atypical pneumonia" is often used to describe pneumonia caused by <em>C. pneumoniae.</em></p><p>Atypical pneumonia refers to pneumonia caused by <em>C. pneumoniae </em>and other bacteria including <em>Mycoplasma pneumoniae</em>,<em> Legionella pneumophila </em>and <em>Legionella</em> species, <em>C. psittaci</em>, and <em>Coxiella burnetii.</em> The origin of the term "atypical" is a matter of debate. The term may refer to the fact that these organisms are not "typical" bacteria that cannot be identified by standard microbiologic techniques. Others suggest that atypical refers to the mild nature of the pneumonia caused by some of these organisms compared with pneumonia caused by <em>Streptococcus pneumoniae</em> [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1280373340"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Rates of <em>C. pneumoniae</em> infection in adults with community-acquired pneumonia (CAP) vary widely among studies, ranging from &lt;1 to 20 percent of cases in which a pathogen was identified [<a href="#rid2">2-13</a>]. The wide range in reported prevalence is likely due to variability in diagnostic methods used and potential cyclic patterns of illness or clustering of cases. Without a reliable reference standard for diagnosis, prevalence cannot be precisely or accurately determined. Rates of infection appear to be higher in patients with mild infection seen in the ambulatory setting and decline in patients with increasing disease severity, including hospitalized patients and those admitted to the intensive care unit (ICU) [<a href="#rid5">5,6,9</a>].</p><p>The overall seroprevalence of <em>C. pneumoniae</em> is about 50 to 85 percent across continents, suggesting that infection is often asymptomatic and that <em>C. pneumoniae </em>is a ubiquitous organism found worldwide [<a href="#rid14">14-18</a>]. Seroprevalence appears to increase with age, with antibodies detectable in &lt;10 percent of children under 10 years old, 30 to 40 percent of teenagers, and 50 percent of middle-aged adults [<a href="#rid15">15</a>]. Seroprevalence may be overestimated because the serologic assays used for the detection of <em>C. pneumoniae</em> can cross-react with other <em>Chlamydia </em>species [<a href="#rid19">19</a>]. Many patients with culture-documented <em>C. pneumoniae</em> pneumonia, especially children, do not develop antibody responses that are detectable with currently available methods [<a href="#rid20">20,21</a>]. The rate of <em>C. pneumoniae</em> infection in children as determined by culture and polymerase chain reaction is similar to that found in adults [<a href="#rid21">21</a>].</p><p><em>C. pneumoniae </em>is transmitted from person to person, likely via respiratory droplets, small particle aerosolization, and fomites [<a href="#rid20">20,22</a>]. Outbreaks of <em>C. pneumoniae </em>infections have been reported in persons living in close quarters, including residents of long-term care facilities, prisoners, and military personnel [<a href="#rid23">23-31</a>]. Attack rates reported in the literature range from about 10 to 68 percent, with a median of 34 percent [<a href="#rid26">26,32</a>].</p><p class="headingAnchor" id="H2"><span class="h1">MICROBIOLOGY</span></p><p class="headingAnchor" id="H1192260751"><span class="h2">Taxonomy</span><span class="headingEndMark"> — </span><em>C. pneumoniae</em> belongs to the Chlamydiaceae family and <em>Chlamydia</em> genus [<a href="#rid33">33</a>]. The <em>Chlamydia</em> genus contains a total of 11 species [<a href="#rid34">34</a>], 3 of which are pathogenic in humans: <em>C. pneumoniae</em>, <em>C. trachomatis</em>,<em> </em>and <em>C. psittaci </em>[<a href="#rid19">19</a>].</p><p>In 1999, there was a proposal to divide the <em>Chlamydia </em>genus into two genera, <em>Chlamydia </em>and <em>Chlamydophila</em>, based on genetic analysis [<a href="#rid35">35</a>]. Upon further analysis, reclassification was not deemed necessary by the scientific community, and it was agreed that the Chlamydiaceae family contains a single genus, <em>Chlamydia </em>[<a href="#rid36">36,37</a>].</p><p class="headingAnchor" id="H2081942577"><span class="h2">Pathogen</span><span class="headingEndMark"> — </span><em>C. pneumoniae </em>is an obligate intracellular organism. It is one of the smallest prokaryotes, with a genome size of about 1.2 million nucleotides [<a href="#rid38">38,39</a>].</p><p><em>Chlamydia</em> species share several structural and metabolic features that differentiate them from other bacteria. The cell wall of <em>Chlamydia</em> spp contains an inner and outer membrane as well as lipopolysaccharide (LPS), similar to all gram-negative bacteria. However, the chlamydial LPS variant is less endotoxic than in many gram-negative bacteria [<a href="#rid40">40</a>]. <em>Chlamydia</em> spp have very little peptidoglycan between the inner and outer membranes and thus have limited susceptibility to penicillins [<a href="#rid19">19,41</a>].</p><p>Metabolically, <em>Chlamydia </em>species rely on the host cell for host adenosine triphosphate (ATP) for protein synthesis, making replication outside the host cell nonsustainable [<a href="#rid19">19,40</a>]. Among <em>Chlamydia </em>species<em>, C. pneumoniae</em> specifically lacks a tryptophan recovery or biosynthesis pathway, rendering the organism vulnerable to host interferon-gamma-mediated immune control [<a href="#rid42">42</a>] as well as intrinsically resistant to sulfonamides and <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a> [<a href="#rid43">43</a>].</p><p>One of the most unique features of <em>Chlamydia</em> species is that bacterial growth requires a biphasic developmental cycle, with two morphologically distinct infectious and reproductive forms [<a href="#rid19">19,40,43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Elementary body (EB) – The extracellular, metabolically inactive, spore-like infectious form, which is able to survive outside the host cell</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reticulate body (RB) – The intracellular, metabolically active but noninfectious form, which is able to rely on the host cell for replication</p><p></p><p>Aberrant bodies, variants of RBs that are less metabolically active and less infectious than RBs, have been observed in in vitro<em> </em>systems designed to induce persistent infection [<a href="#rid19">19</a>]. The extent to which they are operative in human infection is uncertain.</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The biphasic life cycle of <em>C. pneumoniae</em> plays an important role in pathogenesis. Outside the host, the organism exists as a small, dense elementary body (EB). The EB has a rigid wall, resulting from disulfide cross-linking of envelope proteins, allowing it to survive outside the host for a short amount of time [<a href="#rid40">40</a>].</p><p>Upon infection, the EB attaches to respiratory mucosal epithelial cells and enters the cell through receptor-mediated endocytosis. Following endocytosis, the EB persists within the phagosome and differentiates into a metabolically active reticulate body (RB). The RB replicates within the host cell forming microcolonies, or intracytoplasmic inclusions composed of hundreds of bacteria, within 36 to 72 hours. The RBs reorganize into the smaller, denser EBs, which are released either via cell lysis or exocytosis. The EBs can then go on to infect new cells [<a href="#rid19">19,40</a>].</p><p>During replication, chlamydial antigens are released onto the host cell surface, inducing the host immune response [<a href="#rid40">40</a>]. One critical feature of <em>Chlamydia</em> organisms is that immunity to infection is not long lived. As a result, reinfection is possible [<a href="#rid19">19,40</a>]. In vitro data suggest that Chlamydiae can also cause persistent infection. While persistent infection has not been definitively demonstrated in humans, it is hypothesized to play a role in multiple chronic illnesses [<a href="#rid19">19,43</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Pneumonia caused by <em>C. pneumoniae</em> is similar to other forms of community-acquired pneumonia (CAP) and is characterized by fever, cough, and shortness of breath. Pneumonia due to <em>C. pneumoniae</em> is typically mild; however, severe cases, cases complicated by pleural effusion and empyema [<a href="#rid44">44</a>], intensive care unit admission, and death have been reported [<a href="#rid6">6,30,45</a>].</p><p>Although there are no clinical features that clearly distinguish pneumonia caused by <em>C. pneumoniae </em>from pneumonia due to other causes, small case series suggest that upper respiratory involvement such as pharyngitis, laryngitis, and sinusitis may occur more frequently with <em>C. pneumoniae</em> and that a gradual onset of illness is common<em> </em>[<a href="#rid30">30,45-47</a>]. These features are also frequent in patients with pneumonia due to <em>M. pneumoniae.</em></p><p>White blood cell counts are typically normal or mildly elevated [<a href="#rid11">11,48</a>]. Chest radiograph findings are usually nonspecific. The most commonly reported findings are unilateral alveolar opacities [<a href="#rid49">49,50</a>]; lobar opacification is reported to be less common than with <em>S. pneumoniae </em>[<a href="#rid49">49</a>]<em>.</em></p><p>The overall spectrum of illness associated with <em>C. pneumoniae </em>is wide, ranging from asymptomatic infection to life-threatening disease. The majority of infections are asymptomatic [<a href="#rid14">14,17</a>]. Other reported manifestations include pharyngitis, laryngitis, otitis media, and bronchitis [<a href="#rid30">30,51</a>]. Reports of acute infections outside the respiratory tract are rare but exist, including meningoencephalitis [<a href="#rid52">52-54</a>], Guillain-Barré syndrome [<a href="#rid55">55</a>], myocarditis [<a href="#rid56">56-60</a>], and endocarditis [<a href="#rid61">61</a>]. In some of these cases, diagnosis was made by serology alone, and a causal role for <em>C. pneumoniae</em> in these infections is not definitively established. Studies from China and Italy have found that patients with severe acute respiratory syndrome coronavirus 2 can be coinfected with other respiratory pathogens, including <em>C. pneumoniae </em>and <em>M. pneumoniae</em>, which may be associated with a more severe presentation [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H857159944"><span class="h2">Approach to diagnosis</span><span class="headingEndMark"> — </span>The clinical presentation of pneumonia caused by C. pneumoniae is nonspecific, and there is no defined population for whom testing can be recommended. Thus, we typically individualize our approach to testing based on the patient’s severity of illness, the likelihood that results would change management, and the availability of a polymerase chain reaction (PCR)-based assay.</p><p>When a PCR-based assay is available onsite, we favor testing for most patients as results are typically available within a few hours of testing. A positive test result (in the absence of clinical suspicion for coinfection) is considered diagnostic and can help rapidly direct antibiotic therapy (see <a class="local">'Directed therapy'</a> below). When PCR-based testing is not available onsite, we make the decision to test on a case-by-case basis.</p><p class="headingAnchor" id="H2030142524"><span class="h2">Microbiologic testing</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PCR-based assays</strong> <strong>–</strong> When microbiologic diagnosis is pursued, we use a PCR-based assay. PCR-based assays can be performed on most specimen types, including nasopharyngeal swabs, sputum, and bronchoalveolar lavage fluid [<a href="#rid64">64</a>].</p><p></p><p>There are three US Food and Drug Administration (FDA)-cleared multiplexed PCR respiratory panels that include <em>C. pneumoniae</em> (eg, BioFire FilmArray, GenMark ePlex, Luminex NxTAG Respiratory Pathogen Panel, and QIAstat-Dx Respiratory) [<a href="#rid65">65-69</a>]. Each includes respiratory viruses and <em>M. pneumoniae</em>. The BioFire FilmArray and QIAstat-Dx also includes <em>Bordetella pertussis</em> and <em>B. parapertussis</em>. Studies using these panels have found the performance in adults and children with respiratory illness to be generally equivalent. Identification of <em>C. pneumoniae</em> has been low, &lt;1 percent, which is consistent with epidemiologic studies over the past 10 years [<a href="#rid65">65-68,70</a>]. If the assays are run onsite, the turnaround time is usually one to two hours.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell culture</strong> – Cell culture can have diagnostic yields as high as PCR in some settings [<a href="#rid71">71</a>] and allows for antimicrobial susceptibility testing [<a href="#rid19">19</a>]. However, this method is rarely used as most clinical laboratories are not equipped to culture <em>Chlamydia</em> spp. Culture requires specialized techniques and can take up to a week [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serology</strong> – We do not use serology for diagnosing acute infection due to its poor predictive value. Serologic testing is not FDA approved and requires collection of both acute and convalescent serum spaced four to six weeks apart, which is clinically impractical [<a href="#rid19">19</a>]. Serology is most often used for retrospective diagnosis.</p><p></p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H4212352932"><span class="h2">Empiric therapy</span><span class="headingEndMark"> — </span>For most patients with community-acquired pneumonia (CAP), the etiology is not known at the time of diagnosis, and empiric treatment is appropriate. In the United States, most recommended empiric regimens include an agent that targets both “typical” pathogens (eg, <em>S. pneumoniae</em>, <em>Staphylococcus aureus</em>) as well as atypical pathogens, such as <em>C. pneumoniae</em> [<a href="#rid73">73</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For outpatients, most empiric regimens generally include a macrolide (eg, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>), <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, or a respiratory fluoroquinolone (eg, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>)  (<a class="graphic graphic_algorithm graphicRef111829" href="/d/graphic/111829.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For hospitalized patients not requiring intensive care unit (ICU) admission, treatment with a either a respiratory fluoroquinolone (such as <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>) or treatment with a beta-lactam (such as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a>) plus a macrolide (such as <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>) are first-line options  (<a class="graphic graphic_algorithm graphicRef112543" href="/d/graphic/112543.html" rel="external">algorithm 2</a>).</p><p></p><p>Precise recommendations differ for patients requiring admission to the ICU and may require modification based on severity of illness, patient comorbidities and drug intolerances, local epidemiology, and risk factors for multidrug-resistant organisms. Recommendations for antibiotic selection and duration of therapy vary with treatment setting and are discussed separately. (See  <a class="medical medical_review" href="/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Directed therapy</span><span class="headingEndMark"> — </span><em>Chlamydia </em>spp<em>. </em>are susceptible to antibiotics that target protein and DNA synthesis, with a spectrum similar to <em>M. pneumoniae</em>. </p><p class="bulletIndent1"><span class="glyph">●</span>When a microbiologic diagnosis of <em>C. pneumoniae </em>infection has been made in a patient with pneumonia, we suggest <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> as first-line therapy  (<a class="graphic graphic_table graphicRef113843" href="/d/graphic/113843.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fluoroquinolones, other macrolides, and tetracyclines that have high intracellular penetration are also reasonable options. </p><p></p><p>Our recommendations are derived from the in vitro susceptibility patterns of <em>C. pneumoniae</em>, antibiotic side effect profiles, and limited data from clinical trials. In vitro, <em>C. pneumoniae</em> is susceptible to tetracyclines, fluoroquinolones, and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>. Acquired resistance to these agents does not appear to occur, including when isolates are tested following therapy [<a href="#rid74">74</a>]. Penicillins have limited activity against <em>Chlamydia</em> spp; cephalosporins have no meaningful activity. <em>C. pneumoniae</em> is intrinsically resistant to aminoglycosides, glycopeptides (eg, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>), <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a>, and sulfamethoxazole [<a href="#rid74">74</a>].</p><p>No clinical trial has directly evaluated the efficacy of these antibiotics on clinical outcomes in adults with pneumonia caused by <em>C. pneumoniae, </em>although several studies have evaluated microbiologic efficacy. In evaluation of all-comers with CAP, several large systemic reviews and randomized trials found no difference in mortality when comparing empiric regimens that contain antibiotics that target atypical organisms with those overall [<a href="#rid75">75-78</a>]. However, reduced rates of clinical failure have been detected in a meta-analysis of randomized trials [<a href="#rid78">78</a>] as well as several subgroup analyses of patients with CAP caused by atypical organisms [<a href="#rid75">75-77</a>].</p><p>Subgroup analyses of patients with culture-confirmed <em>C. pneumoniae </em>pneumonia from several clinical trials have demonstrated approximately 80 percent efficacy for microbiologic eradication of the organism from the nasopharynx with 5-day courses of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid79">79,80</a>] and 70 to 100 percent efficacy with 10-day courses of <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a>, or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> [<a href="#rid81">81,82</a>] and 7- to 10-day courses of <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> [<a href="#rid83">83</a>]. Whether microbiologic eradication is necessary for clinical cure is not known.</p><p class="headingAnchor" id="H1499461340"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Pneumonia caused by <em>C. pneumoniae </em>is typically mild, and most patients recover without complications. The associated cough can be prolonged, with a median duration of 21 days and range of 1 to 64 days [<a href="#rid26">26,45</a>]. Mortality is most often reported for atypical pneumonia in aggregate and ranges from about 0 to 4 percent [<a href="#rid9">9,84</a>]. <em>C. pneumoniae</em> has also been associated with asthma [<a href="#rid51">51,85-87</a>] and reactive arthritis [<a href="#rid88">88-90</a>].</p><p class="headingAnchor" id="H3428901921"><span class="h1">INFECTION CONTROL</span><span class="headingEndMark"> — </span><em>C. pneumoniae</em> can be transmitted from person to person, although the precise mode of transmission is not known. The United States Centers for Disease Control and Prevention (CDC) recommend standard precautions for patients in health care facilities with pneumonia caused by <em>C. pneumoniae</em>, as well as for patients with community-acquired pneumonia in whom the cause is not known. We also use standard precautions for isolated cases of pneumonia caused by <em>C. pneumoniae</em>, but enhanced infection control measures include droplet precautions during outbreaks or when there is evidence of intra-facility transmission.</p><p class="headingAnchor" id="H3269254705"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104226.html" rel="external">"Society guideline links: Community-acquired pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H366531256"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology </strong>–<strong> </strong><em>Chlamydia pneumoniae</em> is an obligate intracellular bacterium that causes respiratory tract infections including pharyngitis, bronchitis, and pneumonia. Pneumonia caused by <em>C. pneumoniae</em> is typically community acquired and mild. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>–<strong> </strong>Rates of <em>C. pneumoniae</em> in adults with community-acquired pneumonia (CAP) vary among studies, ranging from &lt;1 to 20 percent of cases in which a pathogen was identified. The incidence appears to be higher in patients with mild infection seen in the ambulatory setting and declines in patients with increasing disease severity, including hospitalized patients and those admitted to intensive care units. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>–<strong> </strong>Pneumonia caused by <em>C. pneumoniae</em> presents similarly to other forms of CAP and is characterized by fever, cough, and shortness of breath. No clinical features clearly distinguish pneumonia caused by <em>C. pneumoniae </em>from pneumonia due to other causes. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to diagnosis </strong>–<strong> </strong>We typically individualize our approach to testing based on the patient's severity of illness, the likelihood that results would change management, and the availability of a polymerase chain reaction (PCR)-based assay. When a PCR-based assay is available onsite, we favor testing for most patients as results are typically available within a few hours of testing. A positive test result (in the absence of clinical suspicion for coinfection) is considered diagnostic and can help rapidly direct antibiotic therapy. (See <a class="local">'Approach to diagnosis'</a> above and <a class="local">'Directed therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Test of choice (PCR) </strong>–<strong> </strong>When microbiologic diagnosis is pursued, we use a PCR-based assay. PCR-based assays can be performed on most specimen types, including nasopharyngeal swabs, sputum, and bronchoalveolar lavage (BAL) fluid. (See <a class="local">'Microbiologic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric treatment </strong>–<strong> </strong>For most patients with CAP, the etiology is not known at the time of diagnosis, and empiric treatment for CAP is appropriate  (<a class="graphic graphic_algorithm graphicRef111829" href="/d/graphic/111829.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef112543" href="/d/graphic/112543.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Initial empiric therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Directed therapy </strong>–<strong> </strong>For patients with microbiologically confirmed <em>C. pneumoniae</em> pneumonia, we suggest <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> as first-line therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We use 500 mg of azithromycin orally on day 1 followed by 250 mg orally once daily on days 2 to 5. Fluoroquinolones, other macrolides, and tetracyclines are also reasonable options. Refer to the table for drug dosing and duration of therapy  (<a class="graphic graphic_table graphicRef113843" href="/d/graphic/113843.html" rel="external">table 1</a>). (See <a class="local">'Directed therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>–<strong> </strong>Most patients with pneumonia caused by <em>C. pneumoniae </em>recover without complications, although cough can be prolonged, with a median duration of 21 days. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H86510258"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dori F Zaleznik, MD, who contributed to an earlier version of this topic review.</p><p>UpToDate also gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Basarab M, Macrae MB, Curtis CM. Atypical pneumonia. Curr Opin Pulm Med 2014; 20:247.</a></li><li><a class="nounderline abstract_t">Marchello C, Dale AP, Thai TN, et al. Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis. Ann Fam Med 2016; 14:552.</a></li><li><a class="nounderline abstract_t">Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202.</a></li><li><a class="nounderline abstract_t">Shibli F, Chazan B, Nitzan O, et al. Etiology of community-acquired pneumonia in hospitalized patients in northern Israel. Isr Med Assoc J 2010; 12:477.</a></li><li><a class="nounderline abstract_t">Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011; 66:340.</a></li><li><a class="nounderline abstract_t">Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101:508.</a></li><li><a class="nounderline abstract_t">Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis 2016; 62:817.</a></li><li><a class="nounderline abstract_t">Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.</a></li><li><a class="nounderline abstract_t">Arnold FW, Summersgill JT, Lajoie AS, et al. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175:1086.</a></li><li><a class="nounderline abstract_t">Capelastegui A, España PP, Bilbao A, et al. Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes. BMC Infect Dis 2012; 12:134.</a></li><li><a class="nounderline abstract_t">Miyashita N, Fukano H, Okimoto N, et al. Clinical presentation of community-acquired Chlamydia pneumoniae pneumonia in adults. Chest 2002; 121:1776.</a></li><li><a class="nounderline abstract_t">Hammerschlag MR, Reznik T, Roblin PM, et al. Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. J Antimicrob Chemother 2003; 51:1025.</a></li><li><a class="nounderline abstract_t">Noguchi S, Yatera K, Kawanami T, et al. Frequency of detection of Chlamydophila pneumoniae using bronchoalveolar lavage fluid in patients with community-onset pneumonia. Respir Investig 2017; 55:357.</a></li><li><a class="nounderline abstract_t">Miyashita N, Niki Y, Nakajima M, et al. Prevalence of asymptomatic infection with Chlamydia pneumoniae in subjectively healthy adults. Chest 2001; 119:1416.</a></li><li><a class="nounderline abstract_t">Grayston JT. Chlamydia pneumoniae, strain TWAR. Chest 1989; 95:664.</a></li><li><a class="nounderline abstract_t">Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161:618.</a></li><li><a class="nounderline abstract_t">Hyman CL, Roblin PM, Gaydos CA, et al. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin Infect Dis 1995; 20:1174.</a></li><li><a class="nounderline abstract_t">Kern DG, Neill MA, Schachter J. A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Evidence of serologic cross-reactivity. Chest 1993; 104:208.</a></li><li class="breakAll">Hammerschlag MR, Kohloff SA, Gaydos CA. Chlamydia pneumoniae. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th Ed, Bennet JE, Dolin R, Blaser MJ (Eds), Elsevier, Philadelphia 2020. p.2323.</li><li><a class="nounderline abstract_t">Hyman CL, Augenbraun MH, Roblin PM, et al. Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR. J Clin Microbiol 1991; 29:2082.</a></li><li><a class="nounderline abstract_t">Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007; 44:568.</a></li><li><a class="nounderline abstract_t">Falsey AR, Walsh EE. Transmission of Chlamydia pneumoniae. J Infect Dis 1993; 168:493.</a></li><li><a class="nounderline abstract_t">Janssens JP. Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med 2005; 11:226.</a></li><li><a class="nounderline abstract_t">Coon RG, Balansay MS, Faix DJ, et al. Chlamydophila pneumoniae infection among Basic Underwater Demolition/SEAL (BUD/S) candidates, Coronado, California, July 2008. Mil Med 2011; 176:320.</a></li><li><a class="nounderline abstract_t">Oktem IM, Ellidokuz H, Sevinc C, et al. PCR and serology were effective for identifying Chlamydophila pneumoniae in a lower respiratory infection outbreak among military recruits. Jpn J Infect Dis 2007; 60:97.</a></li><li><a class="nounderline abstract_t">Conklin L, Adjemian J, Loo J, et al. Investigation of a Chlamydia pneumoniae outbreak in a Federal correctional facility in Texas. Clin Infect Dis 2013; 57:639.</a></li><li><a class="nounderline abstract_t">Troy CJ, Peeling RW, Ellis AG, et al. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA 1997; 277:1214.</a></li><li><a class="nounderline abstract_t">Miyashita N, Ouchi K, Shoji H, et al. Outbreak of Chlamydophila pneumoniae infection in long-term care facilities and an affiliated hospital. J Med Microbiol 2005; 54:1243.</a></li><li><a class="nounderline abstract_t">Fajardo KA, Zorich SC, Voss JD, Thervil JW. Pneumonia Outbreak Caused by Chlamydophila pneumoniae among US Air Force Academy Cadets, Colorado, USA. Emerg Infect Dis 2015; 21:1049.</a></li><li><a class="nounderline abstract_t">Ekman MR, Grayston JT, Visakorpi R, et al. An epidemic of infections due to Chlamydia pneumoniae in military conscripts. Clin Infect Dis 1993; 17:420.</a></li><li><a class="nounderline abstract_t">Clemmons NS, Jordan NN, Brown AD, et al. Outbreak of Chlamydia pneumoniae Infections and X-ray-Confirmed Pneumonia in Army Trainees at Fort Leonard Wood, Missouri, 2014. Mil Med 2019; 184:e196.</a></li><li><a class="nounderline abstract_t">Utsumi M, Makimoto K, Quroshi N, Ashida N. Types of infectious outbreaks and their impact in elderly care facilities: a review of the literature. Age Ageing 2010; 39:299.</a></li><li class="breakAll">National Center for Biotechnology InformationTaxonomy Browser. Accessed May 10, 2017. https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&amp;id=83558&amp;lvl=3&amp;lin=f&amp;keep=1&amp;srchmode=1&amp;unlock.</li><li><a class="nounderline abstract_t">Sachse K, Laroucau K. Two more species of Chlamydia-does it make a difference? Pathog Dis 2015; 73:1.</a></li><li><a class="nounderline abstract_t">Everett KD, Bush RM, Andersen AA. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. Int J Syst Bacteriol 1999; 49 Pt 2:415.</a></li><li><a class="nounderline abstract_t">Greub G. International Committee on Systematics of Prokaryotes. Subcommittee on the taxonomy of the Chlamydiae: minutes of the closed meeting, 21 June 2010, Hof bei Salzburg, Austria. Int J Syst Evol Microbiol 2010; 60:2694.</a></li><li><a class="nounderline abstract_t">Greub G. International Committee on Systematics of Prokaryotes Subcommittee on the taxonomy of Chlamydiae. Minutes of the closed meeting, 31 March 2015, New Orleans, USA. Int J Syst Evol Microbiol 2017; 67:512.</a></li><li><a class="nounderline abstract_t">Shirai M, Hirakawa H, Kimoto M, et al. Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA. Nucleic Acids Res 2000; 28:2311.</a></li><li><a class="nounderline abstract_t">Kalman S, Mitchell W, Marathe R, et al. Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat Genet 1999; 21:385.</a></li><li><a class="nounderline abstract_t">Burillo A, Bouza E. Chlamydophila pneumoniae. Infect Dis Clin North Am 2010; 24:61.</a></li><li><a class="nounderline abstract_t">Jacquier N, Viollier PH, Greub G. The role of peptidoglycan in chlamydial cell division: towards resolving the chlamydial anomaly. FEMS Microbiol Rev 2015; 39:262.</a></li><li><a class="nounderline abstract_t">Chacko A, Barker CJ, Beagley KW, et al. Increased sensitivity to tryptophan bioavailability is a positive adaptation by the human strains of Chlamydia pneumoniae. Mol Microbiol 2014; 93:797.</a></li><li><a class="nounderline abstract_t">Roulis E, Polkinghorne A, Timms P. Chlamydia pneumoniae: modern insights into an ancient pathogen. Trends Microbiol 2013; 21:120.</a></li><li><a class="nounderline abstract_t">Augenbraun MH, Roblin PM, Mandel LJ, et al. Chlamydia pneumoniae pneumonia with pleural effusion: diagnosis by culture. Am J Med 1991; 91:437.</a></li><li><a class="nounderline abstract_t">Kauppinen MT, Saikku P, Kujala P, et al. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 1996; 51:185.</a></li><li><a class="nounderline abstract_t">Chirgwin K, Roblin PM, Gelling M, et al. Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis 1991; 163:757.</a></li><li><a class="nounderline abstract_t">Grayston JT, Aldous MB, Easton A, et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis 1993; 168:1231.</a></li><li><a class="nounderline abstract_t">Puljiz I, Kuzman I, Dakovic-Rode O, et al. Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles. Epidemiol Infect 2006; 134:548.</a></li><li><a class="nounderline abstract_t">Kauppinen MT, Lähde S, Syrjälä H. Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia. Arch Intern Med 1996; 156:1851.</a></li><li><a class="nounderline abstract_t">McConnell CT Jr, Plouffe JF, File TM, et al. Radiographic appearance of Chlamydia pneumoniae (TWAR strain) respiratory infections. CBPIS Study Group. Community-based Pneumonia Incidence Study. Radiology 1994; 192:819.</a></li><li><a class="nounderline abstract_t">Juvonen R, Bloigu A, Paldanius M, et al. Acute Chlamydia pneumoniae infections in asthmatic and non-asthmatic military conscripts during a non-epidemic period. Clin Microbiol Infect 2008; 14:207.</a></li><li><a class="nounderline abstract_t">Anton E, Otegui A, Alonso A. Meningoencephalitis and Chlamydia pneumoniae infection. Eur J Neurol 2000; 7:586.</a></li><li><a class="nounderline abstract_t">Guglielminotti J, Lellouche N, Maury E, et al. Severe meningoencephalitis: an unusual manifestation of Chlamydia pneumoniae infection. Clin Infect Dis 2000; 30:209.</a></li><li><a class="nounderline abstract_t">Socan M, Beovic B, Kese D. Chlamydia pneumonia and meningoencephalitis. N Engl J Med 1994; 331:406.</a></li><li><a class="nounderline abstract_t">Haidl S, Ivarsson S, Bjerre I, Persson K. Guillain-Barré syndrome after Chlamydia pneumoniae infection. N Engl J Med 1992; 326:576.</a></li><li><a class="nounderline abstract_t">Durel CA, Saison J, Chidiac C, Ferry T. A case of interstitial pneumonia, myocarditis and severe sepsis caused by Chlamydia pneumoniae. BMJ Case Rep 2015; 2015.</a></li><li><a class="nounderline abstract_t">Suesaowalak M, Cheung MM, Tucker D, et al. Chlamydophila pneumoniae myopericarditis in a child. Pediatr Cardiol 2009; 30:336.</a></li><li><a class="nounderline abstract_t">Walder G, Gritsch W, Wiedermann CJ, et al. Co-infection with two Chlamydophila species in a case of fulminant myocarditis. Crit Care Med 2007; 35:623.</a></li><li><a class="nounderline abstract_t">Hoefer D, Poelzl G, Kilo J, et al. Early detection and successful therapy of fulminant chlamydia pneumoniae myocarditis. ASAIO J 2005; 51:480.</a></li><li><a class="nounderline abstract_t">Tong CY, Potter F, Worthington E, Mullins P. Chlamydia pneumoniae myocarditis. Lancet 1995; 346:710.</a></li><li><a class="nounderline abstract_t">Gdoura R, Pereyre S, Frikha I, et al. Culture-negative endocarditis due to Chlamydia pneumoniae. J Clin Microbiol 2002; 40:718.</a></li><li><a class="nounderline abstract_t">Ma L, Wang W, Le Grange JM, et al. Coinfection of SARS-CoV-2 and Other Respiratory Pathogens. Infect Drug Resist 2020; 13:3045.</a></li><li><a class="nounderline abstract_t">De Francesco MA, Poiesi C, Gargiulo F, et al. Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. J Infect 2021; 82:e4.</a></li><li><a class="nounderline abstract_t">Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018; 67:e1.</a></li><li><a class="nounderline abstract_t">Leber AL, Everhart K, Daly JA, et al. Multicenter Evaluation of BioFire FilmArray Respiratory Panel 2 for Detection of Viruses and Bacteria in Nasopharyngeal Swab Samples. J Clin Microbiol 2018; 56.</a></li><li><a class="nounderline abstract_t">Lee BR, Hassan F, Jackson MA, Selvarangan R. Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections. J Clin Virol 2019; 110:11.</a></li><li><a class="nounderline abstract_t">Babady NE, England MR, Jurcic Smith KL, et al. Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs. J Clin Microbiol 2018; 56.</a></li><li><a class="nounderline abstract_t">Gonsalves S, Mahony J, Rao A, et al. Multiplexed detection and identification of respiratory pathogens using the NxTAG® respiratory pathogen panel. Methods 2019; 158:61.</a></li><li><a class="nounderline abstract_t">Leber AL, Lisby JG, Hansen G, et al. Multicenter Evaluation of the QIAstat-Dx Respiratory Panel for Detection of Viruses and Bacteria in Nasopharyngeal Swab Specimens. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Fujita J, Kinjo T. Where is Chlamydophila pneumoniae pneumonia? Respir Investig 2020; 58:336.</a></li><li><a class="nounderline abstract_t">Gaydos CA, Roblin PM, Hammerschlag MR, et al. Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients. J Clin Microbiol 1994; 32:903.</a></li><li><a class="nounderline abstract_t">She RC, Thurber A, Hymas WC, et al. Limited utility of culture for Mycoplasma pneumoniae and Chlamydophila pneumoniae for diagnosis of respiratory tract infections. J Clin Microbiol 2010; 48:3380.</a></li><li><a class="nounderline abstract_t">Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.</a></li><li><a class="nounderline abstract_t">Kohlhoff SA, Hammerschlag MR. Treatment of Chlamydial infections: 2014 update. Expert Opin Pharmacother 2015; 16:205.</a></li><li><a class="nounderline abstract_t">Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014; 174:1894.</a></li><li><a class="nounderline abstract_t">Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012; :CD004418.</a></li><li><a class="nounderline abstract_t">Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005; 330:456.</a></li><li><a class="nounderline abstract_t">Eljaaly K, Alshehri S, Aljabri A, et al. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis 2017; 17:385.</a></li><li><a class="nounderline abstract_t">Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother 1998; 42:194.</a></li><li><a class="nounderline abstract_t">Harris JA, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998; 17:865.</a></li><li><a class="nounderline abstract_t">Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 2000; 15:149.</a></li><li><a class="nounderline abstract_t">Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14:471.</a></li><li><a class="nounderline abstract_t">Hammerschlag MR, Roblin PM. Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother 2000; 44:1409.</a></li><li><a class="nounderline abstract_t">Sharma L, Losier A, Tolbert T, et al. Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia. Clin Chest Med 2017; 38:45.</a></li><li><a class="nounderline abstract_t">Asner SA, Jaton K, Kyprianidou S, et al. Chlamydia pneumoniae: possible association with asthma in children. Clin Infect Dis 2014; 58:1198.</a></li><li><a class="nounderline abstract_t">Smith-Norowitz TA, Chotikanatis K, Weaver D, et al. Chlamydia pneumoniae-induced tumour necrosis factor alpha responses are lower in children with asthma compared with non-asthma. BMJ Open Respir Res 2018; 5:e000239.</a></li><li><a class="nounderline abstract_t">Dzhindzhikhashvili MS, Joks R, Smith-Norowitz T, et al. Doxycycline suppresses Chlamydia pneumoniae-mediated increases in ongoing immunoglobulin E and interleukin-4 responses by peripheral blood mononuclear cells of patients with allergic asthma. J Antimicrob Chemother 2013; 68:2363.</a></li><li><a class="nounderline abstract_t">Rizzo A, Domenico MD, Carratelli CR, Paolillo R. The role of Chlamydia and Chlamydophila infections in reactive arthritis. Intern Med 2012; 51:113.</a></li><li><a class="nounderline abstract_t">Melby KK, Kvien TK, Glennås A, Anestad G. Chlamydia pneumoniae as a trigger of reactive arthritis. Scand J Infect Dis 1999; 31:327.</a></li><li><a class="nounderline abstract_t">Carter JD, Hudson AP. The evolving story of Chlamydia-induced reactive arthritis. Curr Opin Rheumatol 2010; 22:424.</a></li></ol></div><div id="topicVersionRevision">Topic 7036 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24626238" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Atypical pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28376442" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of Atypical Pathogens in Patients With Cough and Community-Acquired Pneumonia: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20014950" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21337816" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Etiology of community-acquired pneumonia in hospitalized patients in northern Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21257985" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Microbial aetiology of community-acquired pneumonia and its relation to severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8948274" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26747825" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172429" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332485" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A worldwide perspective of atypical pathogens in community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691449" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12065338" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical presentation of community-acquired Chlamydia pneumoniae pneumonia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654764" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29153416" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Frequency of detection of Chlamydophila pneumoniae using bronchoalveolar lavage fluid in patients with community-onset pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11348947" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence of asymptomatic infection with Chlamydia pneumoniae in subjectively healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2646079" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chlamydia pneumoniae, strain TWAR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2181028" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7619996" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8325072" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Evidence of serologic cross-reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8325072" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Evidence of serologic cross-reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1774340" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243062" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8335994" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Transmission of Chlamydia pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15818184" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pneumonia in the elderly (geriatric) population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21456360" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chlamydophila pneumoniae infection among Basic Underwater Demolition/SEAL (BUD/S) candidates, Coronado, California, July 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515640" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : PCR and serology were effective for identifying Chlamydophila pneumoniae in a lower respiratory infection outbreak among military recruits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23723194" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Investigation of a Chlamydia pneumoniae outbreak in a Federal correctional facility in Texas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9103345" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16278441" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Outbreak of Chlamydophila pneumoniae infection in long-term care facilities and an affiliated hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988545" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pneumonia Outbreak Caused by Chlamydophila pneumoniae among US Air Force Academy Cadets, Colorado, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8218684" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An epidemic of infections due to Chlamydia pneumoniae in military conscripts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30690452" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Outbreak of Chlamydia pneumoniae Infections and X-ray-Confirmed Pneumonia in Army Trainees at Fort Leonard Wood, Missouri, 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332371" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Types of infectious outbreaks and their impact in elderly care facilities: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332371" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Types of infectious outbreaks and their impact in elderly care facilities: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25853999" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Two more species of Chlamydia-does it make a difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10319462" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21048222" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : International Committee on Systematics of Prokaryotes. Subcommittee on the taxonomy of the Chlamydiae: minutes of the closed meeting, 21 June 2010, Hof bei Salzburg, Austria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27995871" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : International Committee on Systematics of Prokaryotes Subcommittee on the taxonomy of Chlamydiae. Minutes of the closed meeting, 31 March 2015, New Orleans, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10871362" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of whole genome sequences of Chlamydia pneumoniae J138 from Japan and CWL029 from USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192388" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparative genomes of Chlamydia pneumoniae and C. trachomatis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171546" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chlamydophila pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25670734" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The role of peptidoglycan in chlamydial cell division: towards resolving the chlamydial anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24989637" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Increased sensitivity to tryptophan bioavailability is a positive adaptation by the human strains of Chlamydia pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23218799" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Chlamydia pneumoniae: modern insights into an ancient pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951390" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Chlamydia pneumoniae pneumonia with pleural effusion: diagnosis by culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8711653" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2010629" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Infection with Chlamydia pneumoniae in Brooklyn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8228356" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16316495" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8790080" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Roentgenographic findings of pneumonia caused by Chlamydia pneumoniae. A comparison with streptococcus pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8058954" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Radiographic appearance of Chlamydia pneumoniae (TWAR strain) respiratory infections. CBPIS Study Group. Community-based Pneumonia Incidence Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070131" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Acute Chlamydia pneumoniae infections in asthmatic and non-asthmatic military conscripts during a non-epidemic period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11054150" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Meningoencephalitis and Chlamydia pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619758" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Severe meningoencephalitis: an unusual manifestation of Chlamydia pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8028636" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chlamydia pneumonia and meningoencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732807" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Guillain-Barrésyndrome after Chlamydia pneumoniae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26338247" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A case of interstitial pneumonia, myocarditis and severe sepsis caused by Chlamydia pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18953592" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Chlamydophila pneumoniae myopericarditis in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17204998" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Co-infection with two Chlamydophila species in a case of fulminant myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16156318" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Early detection and successful therapy of fulminant chlamydia pneumoniae myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7658858" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Chlamydia pneumoniae myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11826006" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Culture-negative endocarditis due to Chlamydia pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32922049" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Coinfection of SARS-CoV-2 and Other Respiratory Pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33482238" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29955859" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29593057" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Multicenter Evaluation of BioFire FilmArray Respiratory Panel 2 for Detection of Viruses and Bacteria in Nasopharyngeal Swab Samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30502640" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29212701" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Multicenter Evaluation of the ePlex Respiratory Pathogen Panel for the Detection of Viral and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660863" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Multiplexed detection and identification of respiratory pathogens using the NxTAG®respiratory pathogen panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32132186" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Multicenter Evaluation of the QIAstat-Dx Respiratory Panel for Detection of Viruses and Bacteria in Nasopharyngeal Swab Specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32703757" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Where is Chlamydophila pneumoniae pneumonia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8027341" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610673" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Limited utility of culture for Mycoplasma pneumoniae and Chlamydophila pneumoniae for diagnosis of respiratory tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25579069" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment of Chlamydial infections: 2014 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25286173" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : β-Lactam monotherapy vsβ-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972070" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15684024" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28576117" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9449287" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9802626" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10854812" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7667050" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10819727" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28159161" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24429432" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Chlamydia pneumoniae: possible association with asthma in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29755754" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Chlamydia pneumoniae-induced tumour necrosis factor alpha responses are lower in children with asthma compared with non-asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23749949" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Doxycycline suppresses Chlamydia pneumoniae-mediated increases in ongoing immunoglobulin E and interleukin-4 responses by peripheral blood mononuclear cells of patients with allergic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22214635" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The role of Chlamydia and Chlamydophila infections in reactive arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482071" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Chlamydia pneumoniae as a trigger of reactive arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20445454" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The evolving story of Chlamydia-induced reactive arthritis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
